The Clinical Research and Clinical Trials Unit renews its participation in the ISCIII Clinical Research Support Platform

grup 2021_210304_12

The aid granted in the last competitive call for Clinical Research Support Platforms of the Carlos III Health Institute (ISCIII) almost triples that granted in the 2017 call, becoming one of the five best funded units of the 34 that make up the new ISCIII Platform throughout Spain.

The Clinical Research and Clinical Trials Unit (UICEC), led by Dr. Pilar Hereu, is an IDIBELL Platform with functional dependence on the Clinical Pharmacology service of the Bellvitge University Hospital (HUB) and integrated into the Department of Clinical Research of IDIBELL. It provides services to researchers in the exercise of their functions and responsibilities as promoters of clinical research studies and in compliance with current legislation and the rules of good clinical practice.

The activity of the UICEC of IDIBELL has had a sustained growth in the period 2017-2020, going from 26 active projects in 2017 to 45 clinical research studies in 2020, divided into the different tasks that comprise its portfolio of services: monitoring of clinical research studies, project management, administrative processing and management, and pharmacovigilance of clinical trials.

The distribution of these 45 projects has been: 37 studies at the HUB, 3 at the ICO, 2 at IDIBELL and 3 clinical trials by external researchers. In addition, during 2020 the UICEC has also supported the launch of 6 clinical trials that evaluate treatment strategies in Sars-Cov-2 infection.

As member of the ISCIII Clinical Research Support Platform, it is part of the network European Clinical Research Infrastructure Network (ECRIN) and currently provides services to 3 independent international multicenter clinical trials with funding from the H2020 call and with support from ECRIN.

 

 

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

RELATED CONTENT

The Clinical Research and Clinical Trials Unit (UICEC)

Share on:

Scroll to Top